Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus Lifesciences extends Sterling Biotech API business acquisition deadline to Sept 30
Shares of Zydus Lifesciences Ltd ended at ₹1,121.45, up by ₹1.81, or 19.95%, on the BSE.
Zydus Lifesciences enters into JV with Sunshine Healthcare
To establish pharma manufacturing facility in Sri Lanka
Zydus, Sunshine to set up $20 million pharma JV in Sri Lanka
Indian pharmaceutical giant Zydus Lifesciences has partnered with Sri Lanka's Sunshine Healthcare Lanka to establish a new manufacturing facility. This $20 million joint venture, Zydus Sunshine Lifesciences, will be located in the Horana Export Processing Zone. The project aims to boost local drug production, decrease reliance on imports, and improve medicine accessibility.
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
GIC shares dip 4% as Rs 3,088 crore OFS opens for retail investors. Should you participate?
General Insurance Corporation of India shares dropped 4% as the government's OFS opens for retail investors today at a discount. Meanwhile, Zydus Lifesciences successfully completed its cash tender offer for Assertio Holdings Inc., making it a wholly-owned subsidiary. This acquisition aims to boost Zydus's pipeline of innovative drugs.
Zydus Lifesciences among 4 stocks that hit 52-week highs & rallied up to 17% in a month
The Sensex ended marginally higher, while four BSE 200 stocks touched fresh 52-week highs, signaling strong investor confidence. Zydus Lifesciences, Apollo Hospitals, Federal Bank and Adani Ports reached their highest levels in a year, supported by steady recent gains.
Zydus Lifesciences share buyback to open on 4 June: Should you participate or not?
Ahead of the buyback opening, Zydus Life stock was trading 2.5% lower at ₹1,063 apiece on Tuesday, 2 June. Here are the buyback details, along with experts' opinions on whether retail investors should participate.
Zydus Lifesciences Ltd spurts 1.81%, up for five straight sessions
Zydus Lifesciences Ltd is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The stock is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma.
Stocks to Watch for May 29: Zydus Life, Patanjali, RIL, Swiggy, Godfrey Phillips and more
From Zydus Lifesciences raising its buyback price and Reliance Industries announcing its AGM and dividend record date, to PhysicsWallah sharply narrowing Q4 losses on strong revenue growth, here are the stocks to watch ahead of Friday’s trading session.
Zydus Lifesciences hikes share buyback price to Rs 1,260 per share, lowers share count
Zydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The total buyback outlay remains Rs 1,100 crore. The pharma stock has outperformed benchmark indices over the past one year with a 19% rally.
Zydus Life hikes buyback price to ₹1,260; cuts size to 87.30 lakh equity shares
The buyback price has been increased from ₹1,150/share to ₹1,260; the maximum number of equity shares proposed to be bought back has been reduced from 95.65 lakh to 87.30 lakh. Shares of Zydus Lifesciences Ltd ended at ₹1,085.95, up by ₹7, or 0.65%, on the BSE today, May 27.
Zydus Lifesciences arm gets FDA priority review for liver disease drug application
The proposed indication is for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have shown an inadequate response to UDCA, or as monotherapy in patients who are unable to tolerate UDCA. Shares of Zydus Lifesciences Ltd ended at ₹1,085.95, up by ₹7, or 0.65%, on the BSE today, May 27.